Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 2/20 | 0.32 |
| ▸ | USP5 | P45974 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590007 | 0.90 | PARP1 (0.38) | PARP1NSD2ELANE | |
| SCHEMBL1590006 | 0.90 | PARP1 (0.38) | PARP1NSD2ELANE | |
| SCHEMBL1590093 | 0.84 | GAA (0.45) | ELANE | |
| SCHEMBL13114652 | 0.83 | PARP1 (0.38) | PARP1 | |
| SCHEMBL1591142 | 0.77 | P2RX7 (0.39) | P2RX7 | |
| SCHEMBL1589917 | 0.75 | P2RX7 (0.41) | P2RX7 | |
| SCHEMBL1590646 | 0.74 | GAA (0.43) | ELANE | |
| SCHEMBL1590645 | 0.74 | GAA (0.43) | ELANE | |
| SCHEMBL3005172 | 0.72 | PARP1 (0.51) | PARP1NSD2USP5ELANEP2RX7 | |
| SCHEMBL2995176 | 0.72 | P2RX7 (0.32) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1933622-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2011-04-21 | — | — | US | disclosed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | PARP1 1754/4885NSD2 4805/4885USP5 4755/4885 |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | PARP1 1754/4885NSD2 4805/4885USP5 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.